

Applicants: Pablo Rubinstein et al.
Serial No.: 09/855,789
Filed: May 15, 2001
Page 2

Amendments to the Claims:

Please cancel Claims 78-90, 92, 94 and 95 without prejudice or disclaimer, and amend Claim 91 and add new Claims 97-103 as set forth below.

1-90. (Canceled)

91. (Currently amended) A therapeutic product separated ~~obtained~~ from a sample of cord blood or placental blood, wherein the therapeutic product consists essentially of ~~comprises~~ thawed at least 80% of white blood cells contained in the sample, less than all of plasma contained in the sample, ~~cord blood or placental blood~~, and less than 10% of red blood cells contained in the sample, and wherein the therapeutic product has a volume of 10 milliliters to 20 milliliters. ~~cord blood or placental blood, wherein thawed stem, progenitor and mononuclear cells have a viability greater than 90%.~~

92. (Canceled)

93. (Previously presented) The therapeutic product of Claim 91, wherein the therapeutic product has an osmolarity of not more than 300 milliosmols.

94-95. (Canceled)

96. (Previously presented) The therapeutic product of Claim 91, wherein the red cell to white cell count is approximately one hundred (100) to one (1).

97. (New) The therapeutic product of Claim 91, wherein the therapeutic product further consists of an anticoagulant.

98. (New) The therapeutic product of Claim 97, wherein the anticoagulant comprises Citrate, Phosphate, and Dextrose (CPD).

99. (New) The therapeutic product of Claim 91, wherein the therapeutic product further consists of a cryoprotectant.

100. (New) The therapeutic product of Claim 99, wherein the cryoprotectant comprises dimethyl sulfoxide.

101. (New) The therapeutic product of Claim 99, wherein the cryoprotectant comprises dextran.

102. (New) A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample, less than all of plasma contained in the sample, less than 10% of red blood cells contained in the sample, and dimethyl sulfoxide diluted to 50% with dextran.

103. (New) A therapeutic product separated from a sample of cord blood or placental blood, wherein the therapeutic product comprises at least 80% of white blood cells contained in the sample and less than all of plasma contained in the sample, and wherein the red cell to white cell count is approximately one hundred (100) to one (1).